Skip to main content
JACS Au logoLink to JACS Au
. 2026 Jan 20;6(2):1048–1060. doi: 10.1021/jacsau.5c01465

A Cryptic Pocket Allosterically Modulates Oligosaccharide Binding to DC-SIGN

Jonathan Lefèbre 1,2,3, Maurice Besch 1,2,3, Marcelo Daniel Gamarra 4,5, Jan-Oliver Kapp-Joswig 6, Annika Balke 7, Stevan Aleksić 6, Henry Flatau 1,3, Gregor Suchy 1,3, Elena Georgieva 6, Patrick Scheerer 7, Bettina G Keller 6, Carlos Pablo Modenutti 4,5,8, Christoph Rademacher 1,3,*
PMCID: PMC12933331  PMID: 41755834

Abstract

DC-SIGN is a C-type lectin receptor expressed on antigen-presenting cells that is crucial for pathogen recognition and immune modulation. Here, we identify and characterize a previously unrecognized cryptic allosteric pocket in DC-SIGN using molecular dynamics simulations, NMR spectroscopy, cryogenic electron microscopy, and biochemical assays. Rotation of the gatekeeper residue M270 exposes the pocket whose occupancy modulates glycan binding. Mutations M270F and T314A mimic the occupied and unoccupied states of this pocket, respectively, shifting the conformational equilibrium of α-helix 2 and altering the oligosaccharide affinity via the extended carbohydrate binding site. While Ca2+ coordination at the canonical binding site remains unaffected, our data reveal a complex interplay between the Ca2+ binding sites and the canonical and extended glycan binding surfaces. These findings uncover a hierarchical allosteric mechanism that enables selective tuning of glycan affinity and suggest the cryptic pocket as a novel target for drug discovery in C-type lectins.

Keywords: C-type lectin, DC-SIGN, allostery, cryptic pocket, NMR


graphic file with name au5c01465_0008.jpg


graphic file with name au5c01465_0006.jpg

Introduction

Dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) is a Ca2+-dependent glycan binding C-type lectin receptor (CLR) expressed on antigen-presenting cells, including dendritic cells and macrophages. , It plays a central role in bridging innate and adaptive immunity by discriminating self from nonself, facilitating pathogen recognition, cellular adhesion, and immunological synapse formation. − The receptor recognizes a broad range of carbohydrate structures, most prominently high-mannose and fucose-containing glycans, such as Lewis X. − These include glycans from bacterial and fungal pathogens, as well as viral glycoproteins exploited, for example, by HIV-1 and SARS-CoV-2 for cellular entry and dissemination. − DC-SIGN also recognizes self-antigens on endogenous glycoproteins, highlighting the diversity of ligands and outcomes ranging from pathogen uptake and immune activation to tolerance. ,, This biological versatility makes it an attractive target for antiviral and immunomodulatory strategies as well as targeted delivery. ,−

Critical to the function of DC-SIGN is its ability to recognize a diverse repertoire of glycan structures through its carbohydrate recognition domain (CRD). The DC-SIGN CRD binds three Ca2+ ions at its long loop region, one of which is coordinated by the conserved Glu-Pro-Asn (EPN) motif, essential for recognizing mannose and fucose-containing glycans at the canonical carbohydrate binding site (CBS). , To achieve functional binding, DC-SIGN engages not only this canonical binding site but also an extended CBS formed by β-strands β2–4, α-helix α2, and residues of the α2−β2 connecting loop (Figure A). This extended site supports recognition of oligosaccharides in multiple binding modes and contributes to secondary contacts that enhance binding affinity and specificity.

1.

1

DC-SIGN harbors a cryptic secondary site. (A) X-ray structure of DC-SIGN CRD with GlcNAc2Man3 (PDB 1K9I) showing the canonical Ca2+-dependent CBS in the long loop and the extended CBS formed by β2–4, α2, and the α2−β2 loop. A previously identified secondary site between α2 and β1′, 1 and 5 is centered by residue M270. (B) Mixed-solvent MD simulations of the CRD with phenol reveal M270 rotates into an upper cavity (Q306, S307, S310, R312, T314, F374, and F359), opening a hydrophobic cryptic pocket (T261, Y268, F269, M270, F302, L303, and I376). (C) FTMap analysis of the closed (top) and open (bottom) states suggests higher druggability upon cryptic pocket opening. Solvent probe clusters are shown as orange and blue sticks and gray sticks for the closed and open state, respectively. Surface is colored in green according to probe contact frequencies. (D) CSPs observed in 1H–15N HSQC NMR experiments with 20 mM phenol and holo 15N-labeled CRD validate the binding site of phenol at the cryptic pocket. Cα atoms of residues experiencing a CSP > 0.025 ppm are shown as spheres. (E) Resonances of residues M270 and Q306 are shown. Minimal perturbation of M270 suggests limited changes in the amide backbone of the residue. (F) 13C Met labeling provides 1H–13C HSQC NMR spectra of the methionine side chains of residues M316 and M270. (G) Addition of phenol opens the cryptic pocket, as indicated by a CSP induced in the M270 resonance (top). Assignment of the methionine resonances was done using a M270F mutant (bottom). (H) Alphafold3 model of the DC-SIGN ECD tetramer (Figure S4). Adapted from ref . Available under a CC-BY NC 4.0 license. Copyright 2025, Lefèbre et al. (I) Representative 2D class averages of DC-SIGN ECD particles, showing predominantly side and intermediate views, with top views being underrepresented. Scale bar: 230 Å. (J) Cryo-EM map of DC-SIGN ECD showing the expected tetrameric topology, with three of the four CRDs visibly resolved. (K) Rigid body docking of the cryo-EM map to the Alphafold3 model reveals a different arrangement of the CRDs, resulting from high flexibility of the CRD-neck junction. The relative positions of the cryptic pocket, the CBS and the CRD-neck junction are highlighted with dotted circles. The cryo-EM map is deposited in the EMDB under accession EMD-56237.

Under physiological conditions the DC-SIGN extracellular domain (ECD) forms tetramers via its neck region allowing for multivalent recognition of glycans, further amplifying ligand binding by avidity effects, eventually leading to endocytosis and immune signaling. − The cellular response is highly context-dependent and can vary significantly with antigen structure and the glycan involved. − Accordingly, while this multilevel architecture enables functional plasticity, it also raises questions about how glycan binding at the CRD translates into cellular responses, particularly in light of the structure–function relationship that governs signaling and endocytic activity of other CLRs, such as langerin, MGL and CLEC5A. − Understanding conformational dynamics and regulatory mechanisms may enable the rational design of compounds that inhibit, activate, or fine-tune the activity of DC-SIGN in the context of immunity and infection.

Despite its therapeutic potential, designing small molecules that directly target the CBS of DC-SIGN with high selectivity and affinity remains challenging. The site is shallow, polar, and binding usually involves a large entropic penalty due to loop flexibility and solvent exposure, resulting in low-affinity and high promiscuity of DC-SIGN-carbohydrate interactions. , An emerging strategy to circumvent these limitations involves targeting secondary sites that are distinct from the CBS and potentially provide increased selectivity, functional specificity, and new opportunities for therapeutic intervention. In DC-SIGN, fragment screening and computational studies have revealed the presence of several secondary sites, including one distal site between α2, β1′, β1, and β5 that is centered by residue M270 (Figure A). − The same site was later exploited to target DC-SIGN-expressing cells using heteromultivalent liposomes and was suggested to allosterically modulate Ca2+-dependent carbohydrate binding by an unknown mechanism.

In this study, we combined molecular dynamics (MD) simulations, nuclear magnetic resonance (NMR) spectroscopy, and biochemical assays to identify and characterize a previously unrecognized druggable pocket in DC-SIGN, accessible only upon conformational rearrangement. We show that the rotational shift of the “gatekeeper” residue M270 exposes this cryptic pocket whose occupancy modulates glycan binding allosterically at the CBS. Introducing M270F and T314A mutations mimics the occupied and the unoccupied states of the pocket, respectively, and shifts the conformational equilibrium of α2, thereby tuning oligosaccharide affinity via the extended CBS. We excluded a direct effect on the Ca2+ cage but found evidence for a more complex interplay of the Ca2+ sites, the canonical and the extended CBS. Together, these results reveal a hierarchical allosteric mechanism that primes DC-SIGN for selective glycan engagement and opens new avenues for drug discovery targeted at CLRs.

Results

Gatekeeper Residue M270 Controls Cryptic Pocket Opening

Previous fragment screening of DC-SIGN identified hits interacting with secondary sites, while in silico analysis indicated low druggability. ,, To expand our knowledge on the local dynamics and druggability of secondary sites in DC-SIGN, we conducted mixed-solvent MD simulations of the CRD with and without phenol to explore the dynamics of these sites. Simulations in 5% v/v water/phenol mixtures identified hotspots matching previously described secondary sites (Figure S1A). While backbone conformational changes were minimal, a hotspot between α2 and β5 was only revealed upon rotation of the thioether side chain of residue M270 into a small upper cavity at the C-terminal end of α2 (Figure B). This motion expelled water and exposed a hydrophobic cryptic pocket with increased druggability, as predicted by FTMap (Figure C and Figure S1B). Without phenol, the open state was still populated (∼34%), indicating an equilibrium between the open and closed states in the absence of phenol (Figure S1C,D).

To experimentally verify the interaction of small organic molecules with the cryptic pocket, we titrated phenol at high excess to uniformly 15N-labeled DC-SIGN CRD in 1H–15N heteronuclear single quantum coherence (HSQC) NMR experiments. We observed strong chemical shift perturbations (CSPs) in residues of the predicted cryptic pocket as well as the upper cavity, to which the M270 side chain rotates (Figure D). In support of a direct interaction with the pocket, measurements with a previously established M270F mutant that blocks secondary site binding showed significantly less CSPs around that site (Figure S2).

Although 1H–15N HSQC NMR allowed us to infer direct binding to the site around M270, CSPs in the M270 resonance were small (Figure E). Since the mechanism of opening of the pocket largely depends on rotation of the methionine side chain instead of backbone movements, we expressed 13C ε- methyl methionine (13C Met)-labeled CRD and assigned the corresponding 1H–13C resonance of M270 by comparison with spectra of the M270F mutant (Figure F,G and Figure S3). In line with our observations from simulations, the addition of phenol induced a CSP in the M270 resonance, indicative of pocket opening (Figure G).

Finally, to address whether pocket accessibility is preserved in the tetramer, we conducted cryogenic electron microscopy (cryo-EM) experiments on the DC-SIGN ECD (Figure S5). Although resolution was low, the maps confirmed the expected oligomeric architecture with flexible CRD orientation, suggesting exposure of the secondary site under physiological conditions (Figure I–K and Figure S6). In a complementary experiment, 1H–13C transverse relaxation-optimized spectroscopy (TROSY) NMR experiments on 13C Met-labeled DC-SIGN ECD showed CSPs at M270 upon phenol addition, consistent with cryptic site accessibility in solution (Figure S7).

Residues of the Secondary Site Are Hubs in a Ca2+ Responsive Allosteric Network

We have previously hypothesized that binding to the secondary site centered by M270 could allosterically modulate Ca2+-dependent carbohydrate binding of DC-SIGN. As a major hallmark of allosteric modulation is reciprocity, perturbations of the Ca2+-dependent CBS should propagate to the secondary site, detectable as CSPs in HSQC NMR spectra. Therefore, we recorded 1H–13C HSQC NMR spectra of 13C Met-labeled DC-SIGN CRD in the absence (apo) and presence (holo) of Ca2+, as well as under mannose-bound conditions. While mannose had no detectable effect, removal of Ca2+ induced CSPs and line broadening in the M270 side chain resonance, indicating conformational or dynamic changes that originate at the Ca2+ site and extend to the secondary site (Figure S8A,B). Notably, the CSP direction upon Ca2+ removal was opposite to that induced by phenol, and phenol addition to the apo protein shifted the signal back toward the holo state, resulting in a linear correlation of chemical shifts and supporting a model of conformational coupling between the Ca2+ sites and the cryptic pocket (Figure S8C). Complementing these observations, 1H–15N HSQC NMR titrations with CaCl2 revealed widespread CSPs and altered exchange regimes across the CRD, particularly in α2 and β2–4, underscoring global structural rearrangements (Figure S8D–F).

To gain deeper insight into how an allosteric signal could be communicated between the Ca2+ and the secondary site, we performed microsecond-scale all-atom MD simulations of both the apo and holo states of the CRD. We analyzed the normalized mutual information (NMI) between backbone dihedral angles (ϕ−ψ) and side chain dihedral angles (χ) for all pairs of residues, measuring the degree of conformational coupling, therefore revealing networks of communicating residues. , While NMI graphs of the apo state revealed a more fragmented network, the holo state showed increased connectivity, especially within β2–4 and α2 (Figure A and Figure S9).

2.

2

MD simulations and NMI analysis of apo and holo DC-SIGN reveal network hubs. (A) Network representation of the NMI graphs computed for the holo (left) and apo (right) states of DC-SIGN CRD. Edge thickness corresponds to computed NMI values (NMI threshold 0.04). Nodes exceeding a degree of 5 are defined as hubs and additionally as highlights if at least one edge exceeds an NMI value of 0.1. Nodes are scaled based on their importance in the network: Highlight and hub > highlight > hub > none. Nodes are colored according to their functional role in the CRD structure. Residues of the cryptic site and the upper cavity are shown in green and pink, respectively. Residues of the canonical and the extended CBS are shown in gray and light gray, respectively. A clear shift of connectivity toward the extended CBS is observed, when comparing the holo to the apo network (Figure S9). (B) Calculation of edge weighted node degrees from NMI analysis reveals residues with high importance in the holo (blue) and the apo (red) network of the CRD. The Δ node degree (holo – apo node degree) illustrates the importance of each residue in the holo network. (C) and (D) Mapping of Δ node degree on the CRD structure reveals clustering of holo network hubs at the extended carbohydrate site in β2–4 (E358, F359, S360, G361, N362, G363, and W364) and the upper cavity (T314, Q300, Q304, Q306, S307, and S310). (E) In contrast, negative Δ node degrees in residues of the long loop region indicate higher connectivity in the apo state.

This was further confirmed by comparing the node degrees as an indicator of the importance of each residue in the NMI networks. With the exception of a few long loop residues that showed higher node degree in the apo state, as previously reported for the CLR langerin, a broader set of residues in β2–4, α2, and the secondary site acted as network hubs in the holo state but drastically lost importance in the apo state (Figure B–E). Furthermore, analyzing hydrogen bond populations along the MD trajectories revealed significant changes in the same regions of the CRD, indicating that correlated conformations in the NMI network are underlying physical interactions (Table S1). Consistent with our observations from experimental CaCl2 titrations, these differences suggested Ca2+ binding enhanced both local and distant residue interactions. In particular, for residues lining the extended CBS and the upper cavity of the secondary site in β2–4 and α2, a high node degree coincided with conformational changes observed in our 1H–15N HSQC NMR CaCl2 titration experiments.

Mutation of Hub Residues Alters Glycan Binding Properties of DC-SIGN

Overall, our data point to a Ca2+-responsive network that couples the Ca2+ sites to the cryptic pocket, with α2, the conserved hydrophobic core, and β3−β4 at the extended site as central nodes. Accordingly, we reasoned that perturbing NMI hubs or the cryptic pocket would disrupt the network, and tested eight CRD point mutants by 1H–15N HSQC NMR (Note S1). Among the selected mutants, the network hub residue T314A retained near-wildtype mannose affinity yet induced pronounced long-range CSPs > 10 Å away from the mutation site, when compared to the wildtype (Note S1 and Figures S11–S15). As T314 is located in the upper cavity where the M270 side chain rotates upon opening of the cryptic pocket, it lies central between other hubs of the NMI network located in α2, the conserved hydrophobic core, and β3 and β4 involved in the formation of the extended CBS (Figure A). This suggests that T314 also acts as a key residue in allosteric signal transmission from the secondary site. Although less prominent in the NMI analysis, we also selected the mutation M270F of the cryptic pocket gatekeeper residue M270 for experimental validation. As it mimics the cryptic pocket to be occupied by a small-molecule ligand similar to phenol, we reasoned that this could allow us to evaluate the effect of ligand binding on the allosteric network (Figure A).

3.

3

Mutations of network hubs T314 and M270 alter the glycan binding properties of DC-SIGN. (A) M270F mutant mimics pocket occupancy, while T314 in the upper cavity acts as a key holo network hub. (B) DSF curves of the ECDs revealed M270F (T m = 70.4 ± 0.6 °C) to increase and T314A (T m = 63.0 ± 0.4 °C) to slightly decrease thermal stability compared to the wildtype (T m = 64.5 ± 0.1 °C). (C) Scheme of the ManNAcF3 reporter interacting with the canonical CBS. Ca2+-dependent binding of the reporter enables indirect measurement of Ca2+ affinity via R2-filtered 19F NMR. , Adapted from ref . Copyright 2016, American Chemical Society. (D) Binding of the reporter under varying CaCl2 concentrations to the ECD proteins reveals minor differences in Ca2+ affinity but larger differences in maximum R2,obs. EC50 (hill slope): WT: 0.3 mM (2.0), M270F: 0.2 mM (1.4), T314A: 0.6 mM (1.7) (E) Multivalent binding of the oligosaccharide-carrying HRP enzyme to DC-SIGN ECD immobilized on a plate. Binding is evaluated using the peroxidase activity of HRP. Adapted from ref . Available under a CC-BY NC 4.0 license. Copyright 2025, Lefèbre et al. (F) Titration of CaCl2 at a constant HRP concentration to the ECD proteins confirms marginal changes in Ca2+ affinity. EC50 (mean ± SD): WT: 1.0 ± 0.4 mM, M270F: 0.7 ± 0.2 mM, and T314A: 1.2 ± 0.3 mM. (G) Titration of HRP at saturating CaCl2 concentration to the ECD proteins, reveal significant impact of the mutations on glycan binding abilities. EC50 (mean ± SD): WT: 1.8 ± 1.0 μg mL-1, M270F: 0.2 ± 0.2 μg mL–1, T314A: 8.6 ± 0.1 μg mL–1. Means and standard deviations of EC50 and T m values for the HRP and the DSF assays were calculated from two biological replicates, each conducted in two technical replicates.

Considering their proposed importance in the Ca2+-dependent network, we hypothesized that the T314A and M270F mutations could affect folding, oligomerization, and Ca2+ affinity as well as the associated glycan binding characteristics of DC-SIGN. Successful purification of the ECDs via mannan affinity chromatography, dynamic light scattering (DLS), and differential scanning fluorimetry (DSF), indicated the mutants to be correctly folded and in their active tetrameric state, with M270F showing increased stability and T314A slightly reduced stability compared to wildtype (Figure B and Figure S16). To study the effect of the mutations on Ca2+-dependent carbohydrate binding activity, we measured binding of the fluorinated N-acetyl mannosamine analogue reporter (ManNAcF3) at a constant concentration under varying CaCl2 concentrations in 19F NMR R2-filtered NMR (Figure C). , The obtained EC50 for the wildtype protein was in agreement with previously reported affinities for langerin, and a hill slope of >1 indicated cooperative effects as observed for other CLRs with accessory Ca2+ sites. ,, While cooperativity was maintained in both mutants and apparent Ca2+ affinity shifted only marginally, the maximal R2,obs at saturating CaCl2 was higher for M270F and lower for T314A than wildtype (Figure D). We orthogonally confirmed these observations based on CaCl2 titrations using the multivalent binding of the plate-immobilized ECDs to the glycoprotein horseradish peroxidase (HRP) (Figure E,F and Figure S17). Finally, titration of HRP at saturating CaCl2 concentrations revealed a 4-fold decreased affinity for T314A, while the M270F mutant showed 10-fold increased affinity compared to the wildtype (Figure G). Accordingly, while our binding assays suggested only marginal changes in Ca2+ affinity, perturbation of the allosteric network led to a marked shift in glycan binding, with T314A weakening and M270F strengthening engagement.

The Allosteric Network Remodels the Extended Carbohydrate Binding Site

We observed only minor differences in mannose affinity between T314A, M270F, and the wildtype, and titration spectra showed nearly identical CSP trajectories for E347 and N349 of the EPN motif, indicating a conserved mannose binding mode at the canonical CBS (Figure A,C). Nevertheless, residues within the extended site on β3, β4, and α2, which were also identified as NMI hubs, exhibited pronounced CSPs and altered trajectories, especially in T314A (Figure B,C). The involvement of these NMI hubs supports allosteric coupling among the cryptic pocket, the upper cavity, and the extended site. Consistent with this view, changes in binding to glycosylated HRP could point toward remodeling of the extended CBS and altered oligosaccharide binding.

4.

4

Mutations remodel the extended carbohydrate binding site. Interaction of mannose with the canonical CBS formed by Ca2+ site II and E347 and N349 of the EPN motif (A) and the GlcNAc2Man3 oligosaccharide with the extended CBS formed by β2–4, α2, and the α2−β2 connecting loop (B) (PDB ID: 1K9I). (C) 1H–15N HSQC mannose titrations show minor effects on the canonical CBS (e.g., residue N349) but larger CSPs and altered trajectories at the extended CBS (e.g., residues E358 and S360). Wildtype CSP trajectories are boxed and overlaid on mutant spectra.

Therefore, we tested binding of DC-SIGN to the Lewis X trisaccharide, previously shown to engage the extended CBS. 1H–15N HSQC NMR titrations revealed larger CSPs than those with mannose, with line broadening at residues such as F313 in the α2−β2 loop, consistent with stronger involvement of the extended CBS (Figures S18 and S19A,B). Although saturation was not reached, the estimated dissociation constant (K D) matched previously reported values (Figure S19C). M270F bound Lewis X more tightly, while T314A showed decreased affinity and altered CSP trajectories, indicating a different binding mode (Figures S19B,C and S20). Finally, 1H–13C HSQC NMR spectra of 13C Met-labeled wildtype under Lewis X-bound conditions revealed a CSP in the M270 resonance, supporting communication between the extended CBS and the cryptic pocket (Figure S21). Together, these results suggested that monosaccharide binding at the canonical Ca2+ site remains unchanged, whereas the cryptic pocket and upper cavity modulate oligosaccharide binding by reshaping the extended site, and that the conformations of both binding sites are reciprocally coupled.

Network Hub Mutations Shift the Ca2+-Dependent Conformational Equilibrium of α-Helix 2

Our binding studies demonstrated skewing of the interaction of DC-SIGN with oligosaccharides toward lower or higher affinity by inserting mutations in the network. If this observation results from perturbation of the same allosteric network, their effects should be reflected in a concerted conformational response across structural elements involved in allosteric modulation.

To test this, we superposed the 1H–15N HSQC NMR spectra of wildtype, M270F, and T314A and compared the direction and magnitude of chemical shift changes. Several resonances displayed linear displacement alongside a unifying chemical shift vector indicating exchange between two conformational states (Figure S22). The linear chemical shift correlation was most pronounced around the cryptic site in β1′ (e.g., T261, F262, F263, and Q264), in α2 (e.g., Q300 and F302), and in the α2−β2 connecting loop (e.g., R312) (Figure A). Structurally, an orbital π-stacking interaction between F263 and F302 anchors β1′ onto the rest of the CRD structure through α2, whose C-terminal end packs closely against β3 and 4 together with the α2−β2 loop. This provides a continuous surface for recognition of oligosaccharides at the extended CBS. While this could point to a mechanism in which oligosaccharide binding could be modulated by the relative positioning of α2 toward β3 and 4, several residues at the C-terminal end of α2 toward the upper cavity deviated from colinearity, indicating the presence of at least one additional state in that region (Figure A and Figure S22). Given that our MD simulations and the Ca2+ titration indicated that structural changes upon Ca2+ binding could potentially propagate to the upper cavity and the cryptic pocket via α2, we revisited this interaction and evaluated the relationship to our mutants by comparing the apo and holo 1H–15N HSQC NMR spectra of all three proteins (Figure B). Intriguingly, we observed continuation of the linear shift trajectories in several residues, such as F262, F263, Q264, and F302, demonstrating a concerted structural response to the M270F and T314A mutations and Ca2+ binding. In line with our MD simulations, this suggested that a Ca2+-responsive network is at play that can be perturbed by mutating the hub residues.

5.

5

Mutations shift the conformational equilibrium of DC-SIGN by altering the open-closed equilibrium of the cryptic pocket. (A) Residues showing colinear displacement in 1H–15N HSQC NMR spectra upon T314A or M270F mutation (green), versus nonlinear residues at the α2 C-terminal end/upper cavity (red). F263 and F302 form a π-stacking interaction, anchoring β1′ to α2 and the rest of the CRD (Figure S22). (B) Overlay of apo and holo 1H–15N HSQC NMR spectra of the wildtype and the mutant CRDs. (C) Example β1′ resonance following colinear CSPs. T314A shifts beyond the apo state (apo "trap"), while M270F shifts beyond the holo state (holo “trap”). (D) Vector scheme of CHESPA to determine the angle θ between chemical shift vectors of apo to holo wildtype and apo wildtype to apo mutant. A cos­(θ) ≈ 1 indicates conformational similarity to holo wildtype, while cos­(θ) ≈ −1 suggests similarity to the apo wildtype conformation. The resonance of T261 is shown as an example. (E) and (F) CHESPA analysis of the apo and holo spectra revealed resonances of residues in β1′, α2, and the cryptic site to approach cos­(θ) ≈ 1 for M270F but showed cos­(θ) ≈ −1 for T314A, indicating a shift toward the holo and apo state, respectively. Yet, residues of the upper cavity deviate from this trend. (G) This is exemplified by the Q306 chemical shift (left) showing T314A to induce a holo-like state (cos­(θ) ≈ 1) in this residue, while the Q306 resonance in M270F showed nonlinear arrangement (cos­(θ) ≈ −0.6). The scheme shows the proposed constitutive closing or exposure of the pocket for M270F or T314A, respectively. (H) 1H–13C HSQC NMR spectra of apo and holo 13C Met-labeled DC-SIGN CRD T314A interacting with phenol (top) do not show a unifying shift vector as observed for the wildtype (Figure S8C). The apo spectrum (bottom) shows a split resonance for M270, indicating two slowly interchanging states, P1 and P2, that resemble the apo and holo state, respectively. Extraction of the 1H dimension of the apo spectrum (inset) allows for line fitting of the populations as shown in (I). (I) Line fitting apo spectra at increasing temperatures shows a shift toward P1. Van’t Hoff analysis (inset) indicates an endothermic transition (ΔH = +32 kJ mol–1) and a positive entropy change (ΔS = +112 J mol–1 K–1). Uncolored data points were not used for fitting. 1H–13C HSQC NMR spectra of the resonance at different temperatures are shown in Figure S24.

Along trajectories of resonances of residues at the interface of β1′, α2, and the cryptic site, the apo M270F resonances shifted beyond the respective holo wildtype resonances, suggesting the mutant to stabilize a holo-like state, while the T314A mutation appeared to stabilize an apo-like state. As neither M270F nor T314A recovered the wildtype holo state upon removal or addition of Ca2+ in these resonances, respectively, we speculated that the effect induced by the mutations could trap α2 in either a holo or an apo-like conformation independent of Ca2+ (Figure C). Taken together, this indicated that the cryptic pocket and upper cavity skew the Ca2+ responsive two-state equilibrium of α2, thereby modulating the extended site while leaving the canonical CBS and its Ca2+ site largely unchanged.

The T314A Mutation Shifts the Open-Closed Equilibrium of the Cryptic Site toward the Open State

To evaluate the Ca2+-dependent two-state equilibrium of the CRD systematically, we compared the conformational similarity of holo and apo wildtype and the apo mutant spectra using chemical shift projection analysis (CHESPA) of the 1H–15N HSQC NMR spectra. CHESPA compares CSP vectors from mutations or other perturbations to those from an orthosteric reference and uses the cosine of the vector angle θ to quantify conformational similarity to the active or inactive state of the protein (Figure D). Overall, this revealed M270F and T314A to shift the CRD toward the holo state and apo state, respectively (Figure E,F). However, this effect did not apply to the C-terminal end of α2 and the upper cavity, as T314A induced a holo-like state in Q306, while in M270F, the chemical shift changes deviated from colinearity (Figure G). As a previous X-ray structure of DC-SIGN in the open state predicted a hydrogen bond of Q306 to the M270 thioether side chain, we hypothesized that this observation could reflect the inability of the M270F mutant to open the cryptic pocket by rotation of residue 270 into the upper cavity (Figure G and Figure S23). Contrastingly, as we have observed the M270 side chain to resemble the holo state upon phenol binding to apo DC-SIGN wildtype in our 1H–13C HSQC NMR experiments, we reasoned that the holo-like state of Q306 in T314A could indicate a shift in the open-closed equilibrium toward the open species, therefore exposing the hydrophobic cryptic pocket even in the absence of a ligand (Figure G).

As the open-closed conformational equilibrium, and with it the chemical shift of Q306, should be coupled to the M270 side chain dynamics, we recorded 1H–13C HSQC NMR spectra of apo and holo 13C Met-labeled T314A in the presence and absence of phenol and compared them to experiments with the wildtype. In line with our hypothesis of a preferred open state upon mutation, we observed a shift of the M270 resonance in holo T314A beyond the resonance of the wildtype bound to phenol. In the presence of phenol, the T314A trajectory is continued with a CSP of higher magnitude, suggesting that T314A preserves the ability to interact with ligands at the cryptic site (Figure H, top). Intriguingly, removing Ca2+ from T314A revealed a split in the M270 resonance, with a higher populated state that resembled the wildtype bound to phenol and a second state overlapping with the holo T314A M270 resonance (Figure H, bottom). This aligns with our CHESPA data, indicating that even without Ca2+, M270 can adopt a holo-like conformation, with the two distinct peaks in apo spectra indicating slow interconversion between these conformations on the NMR time scale. Analysis of the temperature dependency of the chemical shift showed a trend toward the apo state above ∼298 K, consistent with an entropically driven, endothermic transition confirmed by Van’t Hoff analysis, with Ca2+ release increasing the conformational freedom of the cryptic pocket (Figure I and Figure S24). Together with the CHESPA results and the slow-exchange behavior, the thermodynamic profile strongly suggested that the Ca2+-dependent conformational state of M270 in apo T314A is already biased toward an open conformation, partially decoupling the phenol bound from the Ca2+ bound conformation. This was further supported by the nonlinearity of the CSPs when comparing spectra of apo and holo T314A with and without phenol, indicating that phenol binding perturbs an already open conformation (Figure H and Figure S8C).

Collectively, our NMR data strongly suggested that the mutants T314A and M270F favor an open state or mimic an occupied state, respectively. Thus, we reasoned that the concerted chemical shift response to Ca2+ and the mutations could directly report on the populations of the exposed and bound state of the cryptic pocket. This would indicate that binding to the pocket could shift the structure to a rather Ca2+ bound state, which would, per our NMI analysis and affinity measurements, lead to a higher connectivity and affinity of the extended CBS. In turn, exposure of the hydrophobic pocket to the solvent, as seen in T314A, would destabilize the network at the extended CBS, leading to decreased affinities. Retrospective analysis of published DC-SIGN CRD X-ray structures supported this model, with pocket occupation associated with increased stability around α2 and β3–4 (Note S2 and Figure S25). Finally, in line with a stabilizing effect of closing the cryptic pocket, we found that phenylalanine seems to be evolutionarily favored across human CLRs at the position equivalent to M270 in DC-SIGN (Figure S26).

Discussion

DC-SIGN-glycan interactions are critical for pathogen recognition, immune modulation, and cellular adhesion. ,,,,, Uncovering how these interactions are regulated at a molecular level offers critical insight into how glycan recognition by the DC-SIGN CRD translates into downstream cellular response, informing DC-SIGN-targeted drug discovery. Past work has identified a secondary site that was proposed to allosterically activate carbohydrate binding in DC-SIGN through interactions with a bivalent glycomimetic ligand, but the underlying mechanism remained elusive. Here, we demonstrate that binding to this site underlies cryptic pocket opening, allosterically activating glycan binding via the extended CBS of DC-SIGN.

We propose a model wherein the occupation state of the cryptic pocket modulates glycan binding affinity through conformational changes in α2, adopting either a holo-like or an apo-like state depending on pocket occupancy. Central to this mechanism is M270, a gatekeeper residue whose side chain rotation into an upper cavity enables cryptic pocket opening, exposing a hydrophobic cleft. We identified the M270F and T314A mutations as proxies for the occupied and unoccupied states of the cryptic pocket, increasing or decreasing the glycan affinity, respectively. These phenotypes are linked to a concerted structural response, skewing the Ca2+-dependent conformational equilibrium of DC-SIGN, specifically affecting α2. While T314A traps this region in an apo-like state, M270F stabilizes a conformation resembling the holo state of the wildtype, even in the absence of Ca2+. The helix therefore behaves as a two-state hinge coupling pocket occupancy to glycan recognition.

While interactions with the Ca2+-coordinated EPN motif remain largely unchanged in the mutants, our NMR studies, MD simulations, and glycan binding assays point to the extended CBS as the major site of allosteric regulation. Residues at the interface of α2 and β2–4, including F313, S360, and E358, showed pronounced CSPs upon mutation and were identified as high-connectivity nodes in the network. Previous structural studies have shown that the same residues contribute to glycan specificity and affinity by forming secondary contacts that enable DC-SIGN to accommodate oligosaccharides in distinct geometries. , In contrast, interactions of monosaccharides at the canonical CBS are less variable, and, independent of the glycan involved, uniformly interact with the same hydrogen bond acceptors and donors via their 3-OH and 4-OH groups. These observations suggest that the allosteric mechanism we describe modulates glycan affinity and selectivity by priming and potentially reshaping the extended CBS.

We found that Ca2+ complexation assumed a structural role beyond direct interactions with monosaccharides. Both our MD simulations and NMR studies showed apo DC-SIGN to sample a broader conformational ensemble, similar to what has been described for the related CLRs DC-SIGNR and langerin. , Binding to Ca2+ leads to a reduced rate of interconversion between conformations and higher connectivity, especially affecting residues of the extended site and α2, and also the open-closed conformation of the cryptic pocket. Accordingly, cofactor complexation potentially has a similar effect on DC-SIGN as occupation of the cryptic site, that is, priming the extended CBS for interactions with oligosaccharides. We hypothesize that this effect is mediated by a network of interactions, including an orbital π-π interaction between F263 and F302. Similar π-stacking interactions have been implicated in the oligomerization behavior of the related CLR langerin. Yet, DC-SIGN and langerin oligomers display distinct topology and relative orientation of CRDs, and we observed both mutants to form tetramers similar to the wildtype. , While it is possible that this interaction impacts the relative spatial arrangement of CRDs without affecting tetramerization via the neck domain, changes in affinity of both ECD and CRD suggested intradomain allosteric control. Supporting this mechanism, pocket occupation results in reduced flexibility in α2 and β3 and 4 and increased stability, as suggested by melting temperatures and evolutionary preference for a phenylalanine in the position of M270. While reduced flexibility of the CBS as affinity-driving factor in CLRs has not been investigated so far, studies on other glycan binding proteins, for instance galectins, have shown that a preorganized carbohydrate recognition domain and conformationally restricted glycan ligands can substantially diminish the entropic penalty associated with binding of conformationally flexible glycans, thereby enhancing overall affinity and shaping selectivity. ,

While the dominant two-state equilibrium is centered around α2, several observations also pointed toward extensive dynamics connecting the canonical CBS, the extended site, and the Ca2+ sites. First, residues such as E358, S360, and F313 show large mutation-induced CSPs that did not follow linear chemical shift behavior, suggesting the presence of intermediate states beyond a simple two-state model. Second, these same residues are also perturbed upon monosaccharide binding, despite being spatially distant from the canonical Ca2+-coordinated site, indicating that the canonical and extended sites are also structurally linked. Third, previous studies on the closely related CLR DC-SIGNR have shown interdependence of Ca2+ binding at the accessory Ca2+ sites and glycan binding. , Therefore, subtle changes in the Ca2+ affinity of DC-SIGN in our binding assays might also be rooted in our setup, only indirectly measuring Ca2+ affinity via glycan binding. Finally, as we observed positive cooperativity between the Ca2+ sites of the CRD, several additional conformations of the long loop region and adjacent sites are possible. ,

Taken together, our observations draw a complex picture of hierarchical allosteric modulation of DC-SIGN with both local and global dynamics differentially affecting the outcome of glycan binding. Previous studies on DC-SIGN have described a relationship between glycan binding dependent effects on both endocytosis and signaling. ,,,, Thus, it is tempting to speculate whether the allosteric mechanism described here also translates into broader receptor-level response under physiological conditions as suggested for other CLRs. ,

Although the currently available data did not allow us to clearly separate the different effects and their contributions, the integration of an allosteric cryptic site into the network suggests that this complex interplay can be modulated by small molecules. In this context, our results also highlight the potential of combining data from simulations with subsequent experimental validation by NMR to identify hidden cryptic sites in proteins with low druggability. Cryptic pockets have emerged as useful entry points for ligand discovery targeting proteins with primary sites of low druggability, and evidence from other CLRs suggests that structurally analogous pockets may occur more broadly within the C-type lectin-like domain (CTLD) fold. , In support of this, our sequence analysis showed conservation of several residues that shape this pocket, including the position corresponding to M270 and the surrounding framework residues, suggesting that the structural capacity to form such a cavity is maintained across multiple CLRs. At the same time, the availability of the pocket will depend on whether the upper cavity, showing much lower sequence conservation, can accommodate the rotating side chain, as seen in DC-SIGN. For example, a structurally equivalent allosteric cryptic pocket has been described in the Ca2+-independent CLR NKG2D, where the same cavity forms through rotation of F113 in a manner that mirrors the movement of M270 in DC-SIGN. These observations indicate that the structural capacity for such a cryptic site may be conserved, although its functional accessibility is likely CLR-specific and requires further comparative analysis.

Taken together, while secondary sites and in some cases allosteric mechanisms have been described for other CLRs, the present study is, to the best of our knowledge, the first description of a cryptic pocket and its functional effect identified in a glycan binding CLR. ,,,,, Building on previously identified fragment hits that engage this region, the cryptic pocket conformation defined here now provides a structural basis for future efforts aimed at designing small-molecule allosteric modulators of DC-SIGN. By enabling selective tuning of extended CBS engagement without disrupting Ca2+ coordination or glycan specificity at the canonical CBS, targeting the site identified here could, for example, enable fine-tuning of cell–cell and cell-pathogen interactions, eventually tuning the immunological response to specific glycans. As other glycan binding CLRs suffer from low druggability similar to DC-SIGN, we envision our approach to equally stimulate drug discovery campaigns targeting other pharmaceutically relevant members of this protein family.

Supplementary Material

au5c01465_si_001.pdf (3.4MB, pdf)

Acknowledgments

We would like to thank the NMR facility at the Department of Pharmaceutical Sciences, Faculty of Life Sciences, University of Vienna, for providing critical support and access to instrumentation for this work. C.P.M. thanks the German Academic Exchange Service (DAAD) for financial support.

Glossary

Abbreviations

DC-SIGN

dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin

CLR

C-type lectin receptor

CRD

carbohydrate recognition domain

CBS

carbohydrate binding site

ECD

extracellular domain

MD

molecular dynamics

NMR

nuclear magnetic resonance

cryo-EM

cryogenic electron microscopy

DLS

dynamic light scattering

DSF

differential scanning fluorimetry

CHESPA

chemical shift projection analysis

NMI

normalized mutual information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/jacsau.5c01465.

  • Experimental procedures, supplementary notes describing mutant selections (Note S1) and retrospective analysis of X-ray structures (Note S2), supplementary Figures S1–S26, and supplementary Table S1 (PDF)

†.

Recursion, 41S Rio Grande Street, Salt Lake City, UT 84101, USA (S.A.)

Conceptualization: C.R., B.K., C.P.M., and J.L. Methodology: J.L., C.P.M., B.K., J.O.K.J., and P.S. Investigation: J.L. and M.B. conducted protein expression, NMR spectroscopy, and biochemical assays with contributions from H.F. and G.S.; M.D.G. and C.P.M. conducted and analyzed mixed-solvent MD simulations; S.A. and J.O.K.J. conducted and analyzed MD simulations of apo and holo DC-SIGN with support from E.G.; A.B. conducted cryo-EM experiments. Formal analysis: J.L., M.D.G., C.P.M., J.O.K.J., and A.B. Writing – original draft: J.L. and C.R. Writing – review and editing: J.L., C.R., M.B., C.P.M., J.O.K.J., B.K., A.B., and P.S. Resources: C.R., B.K., P.S., and C.P.M. Supervision: C.R., B.K., P.S., and C.P.M. Funding acquisition: C.R., B.K., and P.S.

This work was supported by the European Union’s Horizon 2020 research and innovation program, Marie Skłodowska Curie grant agreement no. 956314 ALLODD (CR, PS, JL); National Research Fund, Luxembourg AFR PhD Grant 17929849 (MB); Deutsche Forschungsgemeinschaft (DFG, IRTG 2662 “Charging into the future”) - project number 434130070 (BK); Deutsche Forschungsgemeinschaft (DFG, SFB1423 “Structural Dynamics of GPCR Activation and Signaling”, project number 421152132, subprojects A01/Z03 (to P.S.); through SFB1078 “Protonation Dynamics in Protein Function”, project number 221545957, subproject B06 (to P.S.), and DFG under Germany’s Excellence StrategyEXC 311 2008/1 (UniSysCat)390540038 (Research Unit E) (A.B. and P.S.).

The authors declare no competing financial interest.

References

  1. Geijtenbeek T. B. H., Torensma R., Vliet S. J. v., Duijnhoven G. C. F. v., Adema G. J., Kooyk Y. v., Figdor C. G.. Identification of DC-SIGN, a Novel Dendritic Cell–Specific ICAM-3 Receptor that Supports Primary Immune Responses. Cell. 2000;100(5):575–585. doi: 10.1016/s0092-8674(00)80693-5. [DOI] [PubMed] [Google Scholar]
  2. Puig-Kroger A., Serrano-Gomez D., Caparros E., Dominguez-Soto A., Relloso M., Colmenares M., Martinez-Munoz L., Longo N., Sanchez-Sanchez N., Rincon M.. et al. Regulated expression of the pathogen receptor dendritic cell-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin in THP-1 human leukemic cells, monocytes, and macrophages. J. Biol. Chem. 2004;279(24):25680–25688. doi: 10.1074/jbc.M311516200. [DOI] [PubMed] [Google Scholar]
  3. Gringhuis S. I., Dunnen J. d., Litjens M., Hof B. v. h., Kooyk Y. v., Geijtenbeek Teunis B. H.. C-Type Lectin DC-SIGN Modulates Toll-like Receptor Signaling via Raf-1 Kinase-Dependent Acetylation of Transcription Factor NF-κB. Immunity. 2007;26(5):605–616. doi: 10.1016/j.immuni.2007.03.012. [DOI] [PubMed] [Google Scholar]
  4. Engering A., Geijtenbeek T. B. H., Vliet S. J. v., Wijers M., Liempt E. v., Demaurex N., Lanzavecchia A., Fransen J., Figdor C. G., Piguet V.. et al. The Dendritic Cell-Specific Adhesion Receptor DC-SIGN Internalizes Antigen for Presentation to T Cells. J. Immunol. 2002;168(5):2118–2126. doi: 10.4049/jimmunol.168.5.2118. [DOI] [PubMed] [Google Scholar]
  5. Kooyk Y. V., Geijtenbeek T. B. H.. A novel adhesion pathway that regulates dendritic cell trafficking and T cell interactions. Immunol. Rev. 2002;186(1):47–56. doi: 10.1034/j.1600-065x.2002.18605.x. [DOI] [PubMed] [Google Scholar]
  6. Moris A., Nobile C., Buseyne F., Porrot F., Abastado J.-P., Schwartz O.. DC-SIGN promotes exogenous MHC-I–restricted HIV-1 antigen presentation. Blood. 2004;103(7):2648–2654. doi: 10.1182/blood-2003-07-2532. [DOI] [PubMed] [Google Scholar]
  7. Neumann A. K., Thompson N. L., Jacobson K.. Distribution and lateral mobility of DC-SIGN on immature dendritic cells–implications for pathogen uptake. J. Cell Sci. 2008;121(5):634–643. doi: 10.1242/jcs.022418. [DOI] [PubMed] [Google Scholar]
  8. Aarnoudse C. A., Bax M., Sánchez-Hernández M., García-Vallejo J. J., Kooyk Y. v.. Glycan modification of the tumor antigen gp100 targets DC-SIGN to enhance dendritic cell induced antigen presentation to T cells. Int. J. Cancer. 2008;122(4):839–846. doi: 10.1002/ijc.23101. [DOI] [PubMed] [Google Scholar]
  9. Hesse C., Ginter W., Förg T., Mayer C. T., Baru A. M., Arnold-Schrauf C., Unger W. W. J., Kalay H., Kooyk Y., Berod L.. et al. In vivo targeting of human DC-SIGN drastically enhances CD8+ T-cell-mediated protective immunity. Eur. J. Immunol. 2013;43(10):2543–2553. doi: 10.1002/eji.201343429. [DOI] [PubMed] [Google Scholar]
  10. Mitchell D. A., Fadden A. J., Drickamer K.. A Novel Mechanism of Carbohydrate Recognition by the C-type Lectins DC-SIGN and DC-SIGNR SUBUNIT ORGANIZATION AND BINDING TO MULTIVALENT LIGANDS*. J. Biol. Chem. 2001;276(31):28939–28945. doi: 10.1074/jbc.M104565200. [DOI] [PubMed] [Google Scholar]
  11. van Liempt E., Bank C. M., Mehta P., Garcia-Vallejo J. J., Kawar Z. S., Geyer R., Alvarez R. A., Cummings R. D., Kooyk Y., van Die I.. Specificity of DC-SIGN for mannose- and fucose-containing glycans. Febs Lett. 2006;580(26):6123–6131. doi: 10.1016/j.febslet.2006.10.009. [DOI] [PubMed] [Google Scholar]
  12. Valverde P., Delgado S., Martínez J. D., Vendeville J.-B., Malassis J., Linclau B., Reichardt N.-C., Cañada F. J., Jiménez-Barbero J., Ardá A.. Molecular Insights into DC-SIGN Binding to Self-Antigens: The Interaction with the Blood Group A/B Antigens. ACS Chem. Biol. 2019;14(7):1660–1671. doi: 10.1021/acschembio.9b00458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Geijtenbeek T. B. H., Kwon D. S., Torensma R., Vliet S. J. v., Duijnhoven G. C. F. v., Middel J., Cornelissen I. L. M. H. A., Nottet H. S. L. M., KewalRamani V. N., Littman D. R.. et al. DC-SIGN, a Dendritic Cell–Specific HIV-1-Binding Protein that Enhances trans-Infection of T Cells. Cell. 2000;100(5):587–597. doi: 10.1016/s0092-8674(00)80694-7. [DOI] [PubMed] [Google Scholar]
  14. Thépaut M., Luczkowiak J., Vivès C., Labiod N., Bally I., Lasala F., Grimoire Y., Fenel D., Sattin S., Thielens N.. et al. DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist. PLoS Pathogens. 2021;17(5):e1009576. doi: 10.1371/journal.ppat.1009576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Tailleux L., Schwartz O., Herrmann J.-L., Pivert E., Jackson M., Amara A., Legres L., Dreher D., Nicod L. P., Gluckman J. C.. et al. DC-SIGN Is the Major Mycobacterium tuberculosis Receptor on Human Dendritic Cells. Journal of Experimental Medicine. 2003;197(1):121–127. doi: 10.1084/jem.20021468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Alvarez C. P., Lasala F. t., Carrillo J., Muñiz O., Corbí A. L., Delgado R.. C-Type Lectins DC-SIGN and L-SIGN Mediate Cellular Entry by Ebola Virus in cis and in trans. Journal of Virology. 2002;76(13):6841–6844. doi: 10.1128/JVI.76.13.6841-6844.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lozach P.-Y., Lortat-Jacob H., Lavalette A. D. L. D., Staropoli I., Foung S., Amara A., Houlès C., Fieschi F., Schwartz O., Virelizier J.-L.. et al. DC-SIGN and L-SIGN Are High Affinity Binding Receptors for Hepatitis C Virus Glycoprotein E2*. J. Biol. Chem. 2003;278(22):20358–20366. doi: 10.1074/jbc.m301284200. [DOI] [PubMed] [Google Scholar]
  18. Appelmelk B. J., Die I. V., Vliet S. J. v., Vandenbroucke-Grauls C. M. J. E., Geijtenbeek T. B. H., Kooyk Y. v.. Cutting Edge: Carbohydrate Profiling Identifies New Pathogens That Interact with Dendritic Cell-Specific ICAM-3-Grabbing Nonintegrin on Dendritic Cells. J. Immunol. 2003;170(4):1635–1639. doi: 10.4049/jimmunol.170.4.1635. [DOI] [PubMed] [Google Scholar]
  19. Cambi A., Netea M. G., Mora-Montes H. M., Gow N. A., Hato S. V., Lowman D. W., Kullberg B. J., Torensma R., Williams D. L., Figdor C. G.. Dendritic cell interaction with Candida albicans critically depends on N-linked mannan. J. Biol. Chem. 2008;283(29):20590–20599. doi: 10.1074/jbc.M709334200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Geijtenbeek T. B. H., Krooshoop D. J. E. B., Bleijs D. A., Vliet S. J. v., Duijnhoven G. C. F. v., Grabovsky V., Alon R., Figdor C. G., Kooyk Y. v.. DC-SIGN–ICAM-2 interaction mediates dendritic cell trafficking. Nature Immunology. 2000;1(4):353–357. doi: 10.1038/79815. [DOI] [PubMed] [Google Scholar]
  21. Conde P., Rodriguez M., van der Touw W., Jimenez A., Burns M., Miller J., Brahmachary M., Chen H. M., Boros P., Rausell-Palamos F.. et al. DC-SIGN­(+) Macrophages Control the Induction of Transplantation Tolerance. Immunity. 2015;42(6):1143–1158. doi: 10.1016/j.immuni.2015.05.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Cramer J., Lakkaichi A., Aliu B., Jakob R. P., Klein S., Cattaneo I., Jiang X., Rabbani S., Schwardt O., Zimmer G.. et al. Sweet Drugs for Bad Bugs: A Glycomimetic Strategy against the DC-SIGN-Mediated Dissemination of SARS-CoV-2. J. Am. Chem. Soc. 2021;143(42):17465–17478. doi: 10.1021/jacs.1c06778. [DOI] [PubMed] [Google Scholar]
  23. Singh S. K., Stephani J., Schaefer M., Kalay H., García-Vallejo J. J., Haan J. d., Saeland E., Sparwasser T., Kooyk Y. v.. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation. Molecular Immunology. 2009;47(2–3):164–174. doi: 10.1016/j.molimm.2009.09.026. [DOI] [PubMed] [Google Scholar]
  24. Garcia-Vallejo J. J., Koning N., Ambrosini M., Kalay H., Vuist I., Sarrami-Forooshani R., Geijtenbeek T. B. H., Kooyk Y. v.. Glycodendrimers prevent HIV transmission via DC-SIGN on dendritic cells. Int. Immunol. 2013;25(4):221–233. doi: 10.1093/intimm/dxs115. [DOI] [PubMed] [Google Scholar]
  25. Feinberg H., Mitchell D. A., Drickamer K., Weis W. I.. Structural Basis for Selective Recognition of Oligosaccharides by DC-SIGN and DC-SIGNR. Science. 2001;294(5549):2163–2166. doi: 10.1126/science.1066371. [DOI] [PubMed] [Google Scholar]
  26. Zelensky A. N., Gready J. E.. The C-type lectin-like domain superfamily. Febs J. 2005;272(24):6179–6217. doi: 10.1111/j.1742-4658.2005.05031.x. [DOI] [PubMed] [Google Scholar]
  27. Feinberg H., Castelli R., Drickamer K., Seeberger P. H., Weis W. I.. Multiple Modes of Binding Enhance the Affinity of DC-SIGN for High Mannose N-Linked Glycans Found on Viral Glycoproteins*. J. Biol. Chem. 2007;282(6):4202–4209. doi: 10.1074/jbc.M609689200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Wawrzinek R., Wamhoff E.-C., Lefebre J., Rentzsch M., Bachem G., Domeniconi G., Schulze J., Fuchsberger F. F., Zhang H., Modenutti C.. et al. A Remote Secondary Binding Pocket Promotes Heteromultivalent Targeting of DC-SIGN. J. Am. Chem. Soc. 2021;143(45):18977–18988. doi: 10.1021/jacs.1c07235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Kozakov D., Grove L. E., Hall D. R., Bohnuud T., Mottarella S. E., Luo L., Xia B., Beglov D., Vajda S.. The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins. Nat. Protoc. 2015;10(5):733–755. doi: 10.1038/nprot.2015.043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Abramson J., Adler J., Dunger J., Evans R., Green T., Pritzel A., Ronneberger O., Willmore L., Ballard A. J., Bambrick J.. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;630(8016):493–500. doi: 10.1038/s41586-024-07487-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Lefebre J., Besch M., Csorba N., Garami K., Orgovan Z., Schlosser G., Bermejo I., Abranyi-Balogh P., Keseru G. M., Rademacher C.. Covalent Activation of the C-type Lectin DC-SIGN. Angew. Chem., Int. Ed. Engl. 2025:e20594. doi: 10.1002/anie.202520594. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Porkolab V., Lepšík M., Ordanini S., John A. S., Roy A. L., Thépaut M., Paci E., Ebel C., Bernardi A., Fieschi F.. Powerful Avidity with a Limited Valency for Virus-Attachment Blockers on DC-SIGN: Combining Chelation and Statistical Rebinding with Structural Plasticity of the Receptor. ACS Cent. Sci. 2023;9(4):709–718. doi: 10.1021/acscentsci.2c01136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Tabarani G., Thépaut M., Stroebel D., Ebel C., Vivès C., Vachette P., Durand D., Fieschi F.. DC-SIGN Neck Domain Is a pH-sensor Controlling Oligomerization SAXS AND HYDRODYNAMIC STUDIES OF EXTRACELLULAR DOMAIN*. J. Biol. Chem. 2009;284(32):21229–21240. doi: 10.1074/jbc.M109.021204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Manzo C., Torreno-Pina J. A., Joosten B., Reinieren-Beeren I., Gualda E. J., Loza-Alvarez P., Figdor C. G., Garcia-Parajo M. F., Cambi A.. The Neck Region of the C-type Lectin DC-SIGN Regulates Its Surface Spatiotemporal Organization and Virus-binding Capacity on Antigen-presenting Cells*. J. Biol. Chem. 2012;287(46):38946–38955. doi: 10.1074/jbc.M112.380121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Feinberg H., Guo Y., Mitchell D. A., Drickamer K., Weis W. I.. Extended Neck Regions Stabilize Tetramers of the Receptors DC-SIGN and DC-SIGNR*. J. Biol. Chem. 2005;280(2):1327–1335. doi: 10.1074/jbc.M409925200. [DOI] [PubMed] [Google Scholar]
  36. Jarvis C. M., Zwick D. B., Grim J. C., Alam M. M., Prost L. R., Gardiner J. C., Park S., Zimdars L. L., Sherer N. M., Kiessling L. L.. Antigen structure affects cellular routing through DC-SIGN. Proc. Natl. Acad. Sci. U. S. A. 2019;116(30):14862–14867. doi: 10.1073/pnas.1820165116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. García-Vallejo J. J., Bloem K., Knippels L. M. J., Garssen J., Vliet S. J. v., Kooyk Y. v.. The Consequences of Multiple Simultaneous C-Type Lectin–Ligand Interactions: DCIR Alters the Endo-Lysosomal Routing of DC-SIGN. Front. Immunol. 2015;6(MAR):87. doi: 10.3389/fimmu.2015.00087. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Gringhuis S. I., Kaptein T. M., Wevers B. A., Mesman A. W., Geijtenbeek T. B. H.. Fucose-specific DC-SIGN signalling directs T helper cell type-2 responses via IKKε- and CYLD-dependent Bcl3 activation. Nat. Commun. 2014;5(1):3898. doi: 10.1038/ncomms4898. [DOI] [PubMed] [Google Scholar]
  39. Gringhuis S. I., Dunnen J. d., Litjens M., Vlist M. v. d., Geijtenbeek T. B. H.. Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV-1 and Helicobacter pylori. Nat. Immunol. 2009;10(10):1081–1088. doi: 10.1038/ni.1778. [DOI] [PubMed] [Google Scholar]
  40. Watson A. A., Lebedev A. A., Hall B. A., Fenton-May A. E., Vagin A. A., Dejnirattisai W., Felce J., Mongkolsapaya J., Palma A. S., Liu Y.. et al. Structural Flexibility of the Macrophage Dengue Virus Receptor CLEC5A IMPLICATIONS FOR LIGAND BINDING AND SIGNALING*. J. Biol. Chem. 2011;286(27):24208–24218. doi: 10.1074/jbc.M111.226142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Diniz A., Coelho H., Dias J. S., Vliet S. J. V., Jiménez-Barbero J., Corzana F., Cabrita E. J., Marcelo F.. The Plasticity of the Carbohydrate Recognition Domain Dictates the Exquisite Mechanism of Binding of Human Macrophage Galactose-Type Lectin. Chem. – Eur. J. 2019;25(61):13945–13955. doi: 10.1002/chem.201902780. [DOI] [PubMed] [Google Scholar]
  42. Joswig J.-O., Anders J., Zhang H., Rademacher C., Keller B. G.. The molecular basis for the pH-dependent calcium affinity of the pattern recognition receptor langerin. J. Biol. Chem. 2021;296:100718. doi: 10.1016/j.jbc.2021.100718. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Hanske J., Aleksić S., Ballaschk M., Jurk M., Shanina E., Beerbaum M., Schmieder P., Keller B. G., Rademacher C.. Intradomain Allosteric Network Modulates Calcium Affinity of the C-Type Lectin Receptor Langerin. J. Am. Chem. Soc. 2016;138(37):12176–12186. doi: 10.1021/jacs.6b05458. [DOI] [PubMed] [Google Scholar]
  44. Sager C. P., Eriş D., Smieško M., Hevey R., Ernst B.. What contributes to an effective mannose recognition domain? Beilstein J. Org. Chem. 2017;13(1):2584–2595. doi: 10.3762/bjoc.13.255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Ernst B., Magnani J. L.. From carbohydrate leads to glycomimetic drugs. Nat. Rev. Drug Discov. 2009;8(8):661–677. doi: 10.1038/nrd2852. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Lefèbre J., Falk T., Ning Y., Rademacher C.. Secondary Sites of the C-type Lectin-Like Fold. Chem. - Eur. J. 2024;30(30):e202400660. doi: 10.1002/chem.202400660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Aretz J., Anumala U. R., Fuchsberger F. F., Molavi N., Ziebart N., Zhang H., Nazaré M., Rademacher C.. Allosteric Inhibition of a Mammalian Lectin. J. Am. Chem. Soc. 2018;140(44):14915–14925. doi: 10.1021/jacs.8b08644. [DOI] [PubMed] [Google Scholar]
  48. Schulze J., Baukmann H., Wawrzinek R., Fuchsberger F. F., Specker E., Aretz J., Nazaré M., Rademacher C.. CellFy: A Cell-Based Fragment Screen against C-Type Lectins. ACS Chem. Biol. 2018;13(12):3229–3235. doi: 10.1021/acschembio.8b00875. [DOI] [PubMed] [Google Scholar]
  49. Aretz J., Baukmann H., Shanina E., Hanske J., Wawrzinek R., Zapol’skii V. A., Seeberger P. H., Kaufmann D. E., Rademacher C.. Identification of Multiple Druggable Secondary Sites by Fragment Screening against DC-SIGN. Angew. Chem., Int. Ed. 2017;56(25):7292–7296. doi: 10.1002/anie.201701943. [DOI] [PubMed] [Google Scholar]
  50. Aretz J., Wamhoff E.-C., Hanske J., Heymann D., Rademacher C.. Computational and Experimental Prediction of Human C-Type Lectin Receptor Druggability. Frontiers in Immunology. 2014;5(JUL):323. doi: 10.3389/fimmu.2014.00323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Zhang H., Modenutti C., Nekkanti Y. P. K., Denis M., Bermejo I. A., Lefèbre J., Che K., Kim D., Kagelmacher M., Kurzbach D.. et al. Identification of the Allosteric Binding Site for Thiazolopyrimidine on the C-Type Lectin Langerin. ACS Chem. Biol. 2022;17(10):2728–2733. doi: 10.1021/acschembio.2c00626. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Zhang H., Daněk O., Makarov D., Rádl S., Kim D., Ledvinka J., Vychodilová K., Hlaváč J., Lefèbre J., Denis M.. et al. Drug-like Inhibitors of DC-SIGN Based on a Quinolone Scaffold. ACS Med. Chem. Lett. 2022;13(6):935–942. doi: 10.1021/acsmedchemlett.2c00067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Borrok M. J., Kiessling L. L.. Non-carbohydrate Inhibitors of the Lectin DC-SIGN. J. Am. Chem. Soc. 2007;129(42):12780–12785. doi: 10.1021/ja072944v. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Arcon J. P., Defelipe L. A., Modenutti C. P., Lopez E. D., Alvarez-Garcia D., Barril X., Turjanski A. G., Marti M. A.. Molecular Dynamics in Mixed Solvents Reveals Protein-Ligand Interactions, Improves Docking, and Allows Accurate Binding Free Energy Predictions. J. Chem. Inf Model. 2017;57(4):846–863. doi: 10.1021/acs.jcim.6b00678. [DOI] [PubMed] [Google Scholar]
  55. Cui D. S., Beaumont V., Ginther P. S., Lipchock J. M., Loria J. P.. Leveraging Reciprocity to Identify and Characterize Unknown Allosteric Sites in Protein Tyrosine Phosphatases. J. Mol. Biol. 2017;429(15):2360–2372. doi: 10.1016/j.jmb.2017.06.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Volkman B. F., Lipson D., Wemmer D. E., Kern D.. Two-state allosteric behavior in a single-domain signaling protein. Science. 2001;291(5512):2429–2433. doi: 10.1126/science.291.5512.2429. [DOI] [PubMed] [Google Scholar]
  57. Wamhoff E.-C., Hanske J., Schnirch L., Aretz J., Grube M., Silva D. V., Rademacher C.. 19 F NMR-Guided Design of Glycomimetic Langerin Ligands. ACS Chem. Biol. 2016;11(9):2407–2413. doi: 10.1021/acschembio.6b00561. [DOI] [PubMed] [Google Scholar]
  58. Keller B., Gattin Z., van Gunsteren W. F.. What stabilizes the 3(14)-helix in beta3-peptides? A conformational analysis using molecular simulation. Proteins. 2010;78(7):1677–1690. doi: 10.1002/prot.22685. [DOI] [PubMed] [Google Scholar]
  59. Jégouzo S. A. F., Quintero-Martínez A., Ouyang X., Santos Á. d., Taylor M. E., Drickamer K.. Organization of the extracellular portion of the macrophage galactose receptor: A trimeric cluster of simple binding sites for N-acetylgalactosamine. Glycobiology. 2013;23(7):853–864. doi: 10.1093/glycob/cwt022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Onizuka T., Shimizu H., Moriwaki Y., Nakano T., Kanai S., Shimada I., Takahashi H.. NMR study of ligand release from asialoglycoprotein receptor under solution conditions in early endosomes. Febs J. 2012;279(15):2645–2656. doi: 10.1111/j.1742-4658.2012.08643.x. [DOI] [PubMed] [Google Scholar]
  61. Ng S., Bennett N. J., Schulze J., Gao N., Rademacher C., Derda R.. Genetically-encoded fragment-based discovery of glycopeptide ligands for DC-SIGN. Bioorgan Med. Chem. 2018;26(19):5368–5377. doi: 10.1016/j.bmc.2018.08.036. [DOI] [PubMed] [Google Scholar]
  62. Pederson K., Mitchell D. A., Prestegard J. H.. Structural Characterization of the DC-SIGN–LewisX Complex. Biochemistry. 2014;53(35):5700–5709. doi: 10.1021/bi5005014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Selvaratnam R., Chowdhury S., VanSchouwen B., Melacini G.. Mapping allostery through the covariance analysis of NMR chemical shifts. Proc. Natl. Acad. Sci. U. S. A. 2011;108(15):6133–6138. doi: 10.1073/pnas.1017311108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. VanSchouwen B., Selvaratnam R., Giri R., Lorenz R., Herberg F. W., Kim C., Melacini G.. Mechanism of cAMP Partial Agonism in Protein Kinase G (PKG) J. Biol. Chem. 2015;290(48):28631–28641. doi: 10.1074/jbc.M115.685305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Selvaratnam R., VanSchouwen B., Fogolari F., Mazhab-Jafari Mohammad T., Das R., Melacini G.. The Projection Analysis of NMR Chemical Shifts Reveals Extended EPAC Autoinhibition Determinants. Biophys. J. 2012;102(3):630–639. doi: 10.1016/j.bpj.2011.12.030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Guo Y., Feinberg H., Conroy E., Mitchell D. A., Alvarez R., Blixt O., Taylor M. E., Weis W. I., Drickamer K.. Structural basis for distinct ligand-binding and targeting properties of the receptors DC-SIGN and DC-SIGNR. Nat. Struct. Mol. Biol. 2004;11(7):591–598. doi: 10.1038/nsmb784. [DOI] [PubMed] [Google Scholar]
  67. Padua R. A. P., Sun Y., Marko I., Pitsawong W., Stiller J. B., Otten R., Kern D.. Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2. Nat. Commun. 2018;9(1):4507. doi: 10.1038/s41467-018-06814-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Geijtenbeek T. B. H., Vliet S. J. v., Koppel E. A., Sanchez-Hernandez M., Vandenbroucke-Grauls C. M. J. E., Appelmelk B., Kooyk Y. v.. Mycobacteria Target DC-SIGN to Suppress Dendritic Cell Function. J. Exp. Med. 2003;197(1):7–17. doi: 10.1084/jem.20021229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Menon S., Rosenberg K., Graham S. A., Ward E. M., Taylor M. E., Drickamer K., Leckband D. E.. Binding-site geometry and flexibility in DC-SIGN demonstrated with surface force measurements. Proc. Natl. Acad. Sci. U. S. A. 2009;106(28):11524–11529. doi: 10.1073/pnas.0901783106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Thépaut M., Guzzi C., Sutkeviciute I., Sattin S., Ribeiro-Viana R., Varga N., Chabrol E., Rojo J., Bernardi A., Angulo J.. et al. Structure of a Glycomimetic Ligand in the Carbohydrate Recognition Domain of C-type Lectin DC-SIGN. Structural Requirements for Selectivity and Ligand Design. J. Am. Chem. Soc. 2013;135(7):2518–2529. doi: 10.1021/ja3053305. [DOI] [PubMed] [Google Scholar]
  71. Probert F., Whittaker S. B. M., Crispin M., Mitchell D. A., Dixon A. M.. Solution NMR Analyses of the C-type Carbohydrate Recognition Domain of DC-SIGNR Protein Reveal Different Binding Modes for HIV-derived Oligosaccharides and Smaller Glycan Fragments. J. Biol. Chem. 2013;288(31):22745–22757. doi: 10.1074/jbc.M113.458299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Chabrol E., Thepaut M., Dezutter-Dambuyant C., Vives C., Marcoux J., Kahn R., Valladeau-Guilemond J., Vachette P., Durand D., Fieschi F.. Alteration of the langerin oligomerization state affects Birbeck granule formation. Biophys. J. 2015;108(3):666–677. doi: 10.1016/j.bpj.2014.10.075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Stambach N. S., Taylor M. E.. Characterization of carbohydrate recognition by langerin, a C-type lectin of Langerhans cells. Glycobiology. 2003;13(5):401–410. doi: 10.1093/glycob/cwg045. [DOI] [PubMed] [Google Scholar]
  74. Gimeno A., Delgado S., Valverde P., Bertuzzi S., Berbis M. A., Echavarren J., Lacetera A., Martin-Santamaria S., Surolia A., Canada F. J.. et al. Minimizing the Entropy Penalty for Ligand Binding: Lessons from the Molecular Recognition of the Histo Blood-Group Antigens by Human Galectin-3. Angew. Chem., Int. Ed. Engl. 2019;58(22):7268–7272. doi: 10.1002/anie.201900723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Guardia C. M., Gauto D. F., Di Lella S., Rabinovich G. A., Marti M. A., Estrin D. A.. An integrated computational analysis of the structure, dynamics, and ligand binding interactions of the human galectin network. J. Chem. Inf Model. 2011;51(8):1918–1930. doi: 10.1021/ci200180h. [DOI] [PubMed] [Google Scholar]
  76. Snyder G. A., Colonna M., Sun P. D.. The Structure of DC-SIGNR with a Portion of its Repeat Domain Lends Insights to Modeling of the Receptor Tetramer. J. Mol. Biol. 2005;347(5):979–989. doi: 10.1016/j.jmb.2005.01.063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Tacken P. J., Ginter W., Berod L., Cruz L. J., Joosten B., Sparwasser T., Figdor C. G., Cambi A.. Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation. Blood. 2011;118(15):4111–4119. doi: 10.1182/blood-2011-04-346957. [DOI] [PubMed] [Google Scholar]
  78. Vajda S., Beglov D., Wakefield A. E., Egbert M., Whitty A.. Cryptic binding sites on proteins: definition, detection, and druggability. Curr. Opin Chem. Biol. 2018;44:1–8. doi: 10.1016/j.cbpa.2018.05.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Thompson A. A., Harbut M. B., Kung P.-P., Karpowich N. K., Branson J. D., Grant J. C., Hagan D., Pascual H. A., Bai G., Zavareh R. B.. et al. Identification of small-molecule protein–protein interaction inhibitors for NKG2D. Proc. Natl. Acad. Sci. U. S. A. 2023;120(18):e2216342120. doi: 10.1073/pnas.2216342120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Preston R. C., Jakob R. P., Binder F. P. C., Sager C. P., Ernst B., Maier T.. E-selectin ligand complexes adopt an extended high-affinity conformation. J. Mol. Cell Biol. 2016;8(1):62–72. doi: 10.1093/jmcb/mjv046. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

au5c01465_si_001.pdf (3.4MB, pdf)

Articles from JACS Au are provided here courtesy of American Chemical Society

RESOURCES